Cargando…
A Point Mutation at C151 of Keap1 of Mice Abrogates NRF2 Signaling, Cytoprotection in Vitro, and Hepatoprotection in Vivo by Bardoxolone Methyl (CDDO-Me)
Bardoxolone methyl (CDDO-Me) is an oleanane triterpenoid in late-stage clinical development for the treatment of patients with diabetic kidney disease. Preclinical studies in rodents demonstrate the efficacy of triterpenoids against carcinogenesis and other diseases, including renal ischemia-reperfu...
Autores principales: | Gatbonton-Schwager, Tonibelle, Yagishita, Yoko, Joshi, Tanvi, Wakabayashi, Nobunao, Srinivasan, Harini, Suzuki, Takafumi, Yamamoto, Masayuki, Kensler, Thomas W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society for Pharmacology and Experimental Therapeutics
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353147/ https://www.ncbi.nlm.nih.gov/pubmed/37188495 http://dx.doi.org/10.1124/molpharm.123.000671 |
Ejemplares similares
-
Current Landscape of NRF2 Biomarkers in Clinical Trials
por: Yagishita, Yoko, et al.
Publicado: (2020) -
Forced Hepatic Expression of NRF2 or NQO1 Impedes Hepatocyte Lipid Accumulation in a Lipodystrophy Mouse Model
por: Wakabayashi, Nobunao, et al.
Publicado: (2023) -
Keap1/Nrf2 pathway in the frontiers of cancer and non-cancer cell metabolism
por: Chartoumpekis, Dionysios V., et al.
Publicado: (2015) -
Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties
por: Wang, Yan-Yang, et al.
Publicado: (2014) -
NRF2 and the Moirai: Life and Death Decisions on Cell Fates
por: Yagishita, Yoko, et al.
Publicado: (2023)